Similar to the free movement of goods and services, the European Commission wants to expand the European Research area in which researchers and innovators can move around in the EU without encountering legal, technological or physical borders. The primary objective is thus to stimulate the mobility of people active in R&I and diffuse the available knowledge all over Europe.
+32 2 550 15 76
During the new programme period, the European Research Area (ERA) will support a new phase in the development of the ERA and synergies with the European Higher Education Area, which may include a stronger focus on supporting the challenges identified in Pillar II, including missions and partnerships, to ensure that the strategic investments made there deliver maximum impact.
Opening the European Research Area to future challenges requires developing synergies with the European Higher Education Area in a complex landscape of universities and research organisations with a view to underpinning open science, innovative entrepreneurial practices, life-long-learning and upskilling talent and breaking down disciplinary and inter-sectoral barriers to match emerging business and societal needs.
Impacts will include better alignment of national reforms and increased programme level collaboration across Member States and Associated Countries, and will help increase the impact of both national and European investments in research and innovation. This will also support other research and innovation priorities including Open Science, citizens’ science, gender equality and other forms of diversity, improving international cooperation, ethics and integrity, and scientific input to other EU policies.
The IMPETUS project, co-funded by the EU, has launched two new calls for Citizen Science projects: the European Union Prize for Citizen Science and the Accelerator: The European Union Prize for Citizen Science recognizes outstanding achievements in the advancement of knowledge through the empowerment of civil society in the development of the fu... read more
The call for the second edition of the EU Award for Gender Equality Champions (HORIZON-WIDERA-2023-GENDER-Prize) has closed on the 25 January 2024. 35 proposals have been submitted. The breakdown per topic is: HORIZON-WIDERA-2023-GENDER-Prize-01 Sustainable Gender Equality: 10 proposals HORIZON-WIDERA-2023-GENDER-Prize-02 Newcomer Gender Equal... read more
The European Commission has cancelled the topic HORIZON-WIDERA-2024-ERA-01-05: Experimentation and exchange of good practices for value creation. The next amendment of the Work Programme will re-introduce the topic with an updated description to be funded under a call in fall 2024. Source: European Commission Funding and tender portal read more
The short survey that NCP Flanders is conducting to collect feedback on its services and suggestions on how they can be further improved is open for five more days. The NCP Flanders team greatly appreciates it if you could take a few minutes of your time (if you haven’t done so yet) to provide your answers and suggestions via this link.... read more
Infosheets contain edited content on aspects related to this programme. They are reviewed at least yearly.
Related links are easy pointers towards external information. We curate the list, but are not liable for the destinations.
Documents contain additional information related to this programme, and are similar to related links.
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.